ES2584190T1 - Proceso para la fabricación de una preparación farmacéutica que contiene acetato de glatiramero - Google Patents
Proceso para la fabricación de una preparación farmacéutica que contiene acetato de glatiramero Download PDFInfo
- Publication number
- ES2584190T1 ES2584190T1 ES15186721.5T ES15186721T ES2584190T1 ES 2584190 T1 ES2584190 T1 ES 2584190T1 ES 15186721 T ES15186721 T ES 15186721T ES 2584190 T1 ES2584190 T1 ES 2584190T1
- Authority
- ES
- Spain
- Prior art keywords
- aqueous pharmaceutical
- filter
- pharmaceutical solution
- temperature
- glatiramer acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title claims abstract 14
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title claims abstract 14
- 229960003776 glatiramer acetate Drugs 0.000 title claims abstract 14
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract 9
- 238000004519 manufacturing process Methods 0.000 title claims abstract 3
- 238000000034 method Methods 0.000 title claims 15
- 239000003186 pharmaceutical solution Substances 0.000 claims abstract 28
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract 11
- 229930195725 Mannitol Natural products 0.000 claims abstract 11
- 235000010355 mannitol Nutrition 0.000 claims abstract 11
- 239000000594 mannitol Substances 0.000 claims abstract 11
- 239000000706 filtrate Substances 0.000 claims abstract 5
- 238000001914 filtration Methods 0.000 claims 11
- 239000008176 lyophilized powder Substances 0.000 claims 2
- 239000011148 porous material Substances 0.000 claims 2
- 229940071643 prefilled syringe Drugs 0.000 claims 2
- 230000001954 sterilising effect Effects 0.000 claims 2
- 238000004659 sterilization and disinfection Methods 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un proceso para preparar una preparación farmacéutica de acetato de glatiramero y manitol en un recipiente adecuado que comprende las etapas de: (i) obtener una solución farmacéutica acuosa de acetato de glatiramero y manitol; (ii) filtrar la solución farmacéutica acuosa a una temperatura por encima de 0 °C a 17,5 °C para producir un filtrado; y (iii) llenar el recipiente adecuado con el filtrado obtenido después de realizar la etapa (ii), para preparar así la preparación farmacéutica de acetato de glatiramero y manitol en el recipiente adecuado.
Claims (15)
- 5101520253035404550556065REIVINDICACIONES1. Un proceso para preparar una preparacion farmaceutica de acetato de glatiramero y manitol en un recipiente adecuado que comprende las etapas de:(i) obtener una solucion farmaceutica acuosa de acetato de glatiramero y manitol;(ii) filtrar la solucion farmaceutica acuosa a una temperatura por encima de 0 °C a 17,5 °C para producir un filtrado; y(iii) llenar el recipiente adecuado con el filtrado obtenido despues de realizar la etapa (ii), para preparar asf la preparacion farmaceutica de acetato de glatiramero y manitol en el recipiente adecuado.
- 2. El proceso de la reivindicacion 1, en el que la etapa de filtracion (ii) comprende filtrar la solucion farmaceutica acuosa a traves de un primer filtro, o un primer filtro y un segundo filtro.
- 3. El proceso de la reivindicacion 2 que comprende ademas la etapa de reducir la temperatura del segundo filtro a una temperatura por encima de 0 °C a 17,5 °C.
- 4. El proceso de la reivindicacion 2 o la reivindicacion 3 que comprende ademas la etapa de reducir la temperatura de la solucion farmaceutica acuosa a una temperatura por encima de 0 °C a 17,5 °C antes de hacerla pasar a traves del segundo filtro.
- 5. El proceso de una cualquiera de las reivindicaciones 2-4, en el que la etapa de filtracion (ii) comprende ademas la etapa de recibir la solucion farmaceutica acuosa filtrada a traves del primer filtro en un recipiente de recepcion, y comprende ademas la etapa de reducir la temperatura de la solucion farmaceutica acuosa a una temperatura por encima de 0 °C a 17,5 °C despues de salir del recipiente de recepcion y antes de entrar entre en el segundo filtro.
- 6. El proceso de una cualquiera de las reivindicaciones 2-5, en el que la etapa de filtracion (ii) comprende ademas la etapa de recibir la solucion farmaceutica acuosa filtrada a traves del primer filtro en un recipiente de recepcion, y comprende ademas la etapa de reducir la temperatura de la solucion farmaceutica acuosa a una temperatura por encima de 0 °C hasta 17,5 °C mientras esta en el recipiente de recepcion.
- 7. El proceso de una cualquiera de las reivindicaciones 2-6 que comprende ademas la etapa de reducir la temperatura del primer filtro a una temperatura por encima de 0 °C a 17,5 °C.
- 8. El proceso de una cualquiera de las reivindicaciones 2-7 que comprende ademas la etapa de reducir la temperatura de la solucion farmaceutica acuosa a una temperatura por encima de 0 °C a 17,5 °C antes de hacerla pasar a traves del primer filtro.
- 9. El proceso de una cualquiera de las reivindicaciones 2-8, en el que la etapa de obtencion (i) comprende(a) combinar la solucion farmaceutica acuosa en un recipiente de combinacion;(b) combinar la solucion farmaceutica acuosa en un recipiente de combinacion y reducir la temperatura de la solucion farmaceutica acuosa a una temperatura por encima de 0 °C a 17,5 °C despues de salir del recipiente de combinacion y antes de entrar en el primer filtro; o(c) combinar la solucion farmaceutica acuosa en un recipiente de combinacion y reducir la temperatura de la solucion farmaceutica acuosa a una temperatura por encima de 0 °C a 17,5 °C mientras esta en el recipiente de combinacion.
- 10. El proceso de una cualquiera de las reivindicaciones 1-9, en el que(a) la etapa de filtracion (ii) comprende filtrar la solucion farmaceutica acuosa a traves de un primer filtro, o un primer filtro y un segundo filtro, y en la que la solucion farmaceutica acuosa se hace pasar a traves del segundo filtro a una velocidad de 3-25 litros/hora; preferentemente a una velocidad de 3-22 litros/hora; mas preferentemente a una velocidad de 3-15 litros/hora; o mas preferentemente a una velocidad de 3-10 litros/hora;(b) la presion durante la etapa de filtracion (ii) y la presion durante la etapa de llenado (iii) se mantienen por debajo de 5,0 bar; o preferentemente por debajo de 3,0 bar; o mas preferentemente por debajo de 2,0 bar; o(c) la etapa de filtracion (ii) comprende filtrar la solucion farmaceutica acuosa a traves de un primer filtro, o un primer filtro y un segundo filtro, y en la que la filtracion se realiza usando un filtro de esterilizacion que tiene un tamano de poro de 0,2 pm o menor, en el que el primer, el segundo o ambos filtros son un filtro de esterilizacion que tiene un tamano de poro de 0,2 pm o menor.
- 11. El proceso de una cualquiera de las reivindicaciones 1-10, en el que(a) la temperatura de la solucion farmaceutica acuosa es entre 0 °C y 14 °C, o preferentemente entre 0 °C y 12 °C, o preferentemente entre 2 °C y 12 °C, o mas preferentemente entre 4 °C y 12 °C; o(b) la temperatura de la solucion farmaceutica acuosa se reduce a una temperatura entre 0 °C y 14 °C, o5101520253035preferentemente entre 0 °C y 12 °C, o preferentemente entre 2 °C y 12 °C, o mas preferentemente entre 4 °C y 12 °C.
- 12. El proceso de una cualquiera de las reivindicaciones 1-11, en el que(a)(i) la preparacion farmaceutica en el recipiente adecuado es una solucion farmaceutica acuosa que comprende 20 mg/ml de acetato de glatiramero y 40 mg/ml manitol, o 40 mg/ml de acetato de glatiramero y 40 mg/ml de manitol,(ii) la preparacion farmaceutica en el recipiente adecuado es una solucion farmaceutica acuosa que tiene un pH en el intervalo de 5,5-7,0, y(iii) la preparacion farmaceutica en el recipiente adecuado es una solucion farmaceutica acuosa que es una solucion acuosa esterilizada que se ha esterilizado por filtracion y sin someter la solucion farmaceutica acuosa a calentamiento, productos qmmicos o exposicion a radiacion; o(b) (i) la preparacion farmaceutica es un polvo liofilizado de acetato de glatiramero y manitol, y(ii) el proceso comprende ademas una etapa de liofilizar el filtrado despues de haberlo llenado en el recipiente adecuado, de manera que se forma un polvo liofilizado de acetato de glatiramero y manitol en el recipiente adecuado.
- 13. El proceso de una cualquiera de las reivindicaciones 1-12, en el que(a) el recipiente adecuado es una jeringa, vial, ampolla, cartucho o infusion; o(b) el recipiente adecuado es una jeringa, en la que la jeringa contiene 1 ml de una solucion farmaceutica acuosa.
- 14. Una jeringa precargada que contiene una solucion farmaceutica acuosa que comprende 40 mg de acetato de glatiramero y 40 mg de manitol, jeringa que se prepara por el proceso de una cualquiera de las reivindicaciones 113, en la que la solucion farmaceutica acuosa(a) tiene una viscosidad en el intervalo de 2,0-3,5 cPa; o(b) tiene una osmolalidad en el intervalo de 275-325 mosmol/kg
- 15. Acetato de glatiramero para su uso en el tratamiento de un paciente humano que padece una forma reincidente de esclerosis multiple, comprendiendo el tratamiento la administracion al paciente humano de tres inyecciones subcutaneas de una dosis de 40 mg/ml de acetato de glatiramero por semana usando la jeringa precargada de la reivindicacion 14.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/608,126 US9155775B1 (en) | 2015-01-28 | 2015-01-28 | Process for manufacturing glatiramer acetate product |
| US201514608126 | 2015-01-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2584190T1 true ES2584190T1 (es) | 2016-09-26 |
| ES2584190T3 ES2584190T3 (es) | 2017-07-20 |
Family
ID=54199060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15186721.5T Active ES2584190T3 (es) | 2015-01-28 | 2015-09-24 | Procedimiento para la fabricación de una preparación farmacéutica que contiene acetato de glatirámero |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US9155775B1 (es) |
| EP (3) | EP3113785A4 (es) |
| JP (2) | JP2018503627A (es) |
| KR (2) | KR102268210B1 (es) |
| CN (1) | CN107530394B (es) |
| AR (1) | AR102096A1 (es) |
| AU (4) | AU2015380381B2 (es) |
| BR (1) | BR112016023736A2 (es) |
| CA (2) | CA2945537C (es) |
| CL (1) | CL2016002607A1 (es) |
| CY (1) | CY1118826T1 (es) |
| DK (1) | DK3050556T3 (es) |
| EA (3) | EA028484B1 (es) |
| ES (1) | ES2584190T3 (es) |
| HK (1) | HK1225309B (es) |
| HR (1) | HRP20170625T1 (es) |
| HU (1) | HUE034059T2 (es) |
| IL (3) | IL247851A0 (es) |
| LT (1) | LT3050556T (es) |
| ME (1) | ME02721B (es) |
| MX (1) | MX352734B (es) |
| PE (1) | PE20170296A1 (es) |
| PL (1) | PL3050556T3 (es) |
| PT (1) | PT3050556T (es) |
| RS (1) | RS55959B1 (es) |
| RU (1) | RU2669769C2 (es) |
| SI (1) | SI3050556T1 (es) |
| UA (1) | UA116060C2 (es) |
| WO (1) | WO2016122722A1 (es) |
| ZA (1) | ZA201606903B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| ES2602977T3 (es) | 2010-10-11 | 2017-02-23 | Teva Pharmaceutical Industries Ltd. | Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero |
| EA201490749A1 (ru) | 2011-10-10 | 2014-09-30 | Тева Фармасьютикал Индастриз Лтд. | Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат |
| NZ630421A (en) | 2012-10-10 | 2018-07-27 | Teva Pharma | Biomarkers predictive for clinical response for glatiramer acetate |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| CN107550853B (zh) * | 2016-06-30 | 2020-06-12 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷注射液的制备方法 |
| US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018178973A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| US20200306516A1 (en) | 2017-08-14 | 2020-10-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof |
| CN112933210A (zh) * | 2019-12-11 | 2021-06-11 | 深圳翰宇药业股份有限公司 | 一种西曲瑞克冻干药物组合物的制备方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| FR2459619B1 (fr) | 1979-06-26 | 1983-07-29 | Agronomique Inst Nat Rech | Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede |
| US4350156A (en) | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
| US4455256A (en) | 1981-05-05 | 1984-06-19 | The Regents Of The University Of California | Bone morphogenetic protein |
| EP0693946B1 (en) | 1993-03-24 | 2001-05-16 | Owen Mumford Limited | Improvements relating to injection devices |
| US5800808A (en) | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| US5631347A (en) | 1995-06-07 | 1997-05-20 | Eli Lilly And Company | Reducing gelation of a fatty acid-acylated protein |
| DE19543737A1 (de) | 1995-11-24 | 1997-05-28 | Hoechst Ag | Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES |
| WO2000005249A2 (en) | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| HU229289B1 (en) | 1998-09-25 | 2013-10-28 | Yeda Res & Dev | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| AU6281599A (en) | 1998-10-02 | 2000-04-26 | Yeda Research And Development Co. Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| AU775073C (en) | 1998-11-12 | 2007-05-03 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD |
| CA2400374A1 (en) | 2000-02-18 | 2001-08-23 | Adrian Gilbert | Oral, nasal and pulmonary dosage formualtions of copolymer 1 |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| HUP0302333A3 (en) | 2000-06-05 | 2005-07-28 | Teva Pharma | The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| DE10158009A1 (de) * | 2001-11-21 | 2003-05-28 | Begerow E Gmbh & Co | Verfahren zur Reduzierung der Gesamtkeimzahl in wäßrigen Dispersionen |
| US7429374B2 (en) | 2001-12-04 | 2008-09-30 | Teva Pharmaceutical Industries, Ltd. | Process for the measurement of the potency of glatiramer acetate |
| CA2411786C (en) | 2002-11-13 | 2009-01-27 | Brantford Chemicals Inc. | A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids |
| US7777006B2 (en) | 2002-12-31 | 2010-08-17 | Csl Behring L.L.C. | Method for purification of alpha-1-antitrypsin |
| EP1592384B1 (en) | 2003-01-21 | 2012-10-31 | Yeda Research And Development Co., Ltd. | Cop 1 for treatment of inflammatory bowel diseases |
| WO2004091573A1 (en) | 2003-03-04 | 2004-10-28 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| US7968511B2 (en) | 2003-05-14 | 2011-06-28 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
| KR101137785B1 (ko) | 2003-07-18 | 2012-04-25 | 백스터 인터내셔널 인코포레이티드 | 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물 |
| KR20060097020A (ko) | 2003-10-31 | 2006-09-13 | 테바 파마슈티컬 인더스트리즈 리미티드 | 약물 전달용 나노입자 |
| EP1701971A2 (en) | 2003-12-31 | 2006-09-20 | F.Hoffmann-La Roche Ag | Peptide synthesis using decanting filter |
| EP1778286A4 (en) | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| US20060194725A1 (en) | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| CA2579038A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| ES2572811T3 (es) | 2004-09-09 | 2016-06-02 | Yeda Research And Development Co., Ltd. | Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos |
| PT2361924E (pt) | 2004-09-09 | 2014-03-13 | Teva Pharma | Processo para a preparação de misturas de acetato de glatirâmero trifluoroacetiílico utilizando ácido bromídrico purificado |
| CN101044188B (zh) | 2004-10-29 | 2010-08-04 | 桑多斯股份公司 | 制备格拉太咪尔的方法 |
| WO2006083608A1 (en) | 2005-02-02 | 2006-08-10 | Teva Pharmaceutical Industries, Ltd. | Process for producing polypeptide mixtures using hydrogenolysis |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| ES2420404T3 (es) | 2005-02-17 | 2013-08-23 | Teva Pharmaceutical Industries Ltd. | Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple |
| WO2006116602A2 (en) | 2005-04-25 | 2006-11-02 | Yeda Research And Development Company | Markers associated with the therapeutic efficacy of glatiramer acetate |
| US20070059798A1 (en) | 2005-09-09 | 2007-03-15 | Alexander Gad | Polypeptides useful for molecular weight determinations |
| WO2007081975A2 (en) | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| WO2007146331A1 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| CN101511862A (zh) | 2006-07-05 | 2009-08-19 | 莫门塔制药股份有限公司 | 制备共聚物-1的改进方法 |
| CN100569282C (zh) | 2006-10-13 | 2009-12-16 | 俞嘉林 | 注射用骨肽冻干剂及其制备方法 |
| AU2008265692A1 (en) | 2007-06-21 | 2008-12-24 | Momenta Pharmaceuticals, Inc. | Copolymer assay |
| US8993722B2 (en) | 2007-07-31 | 2015-03-31 | Natco Pharma Limited | Process for the preparation glatiramer acetate (copolymer-1) |
| WO2009070298A1 (en) | 2007-11-28 | 2009-06-04 | Teva Pharmaceutical Industries, Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
| KR101534422B1 (ko) | 2008-05-14 | 2015-07-09 | 오토노미, 인코포레이티드 | 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법 |
| US8323685B2 (en) | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing compositions containing microparticles |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| EP2275086B1 (en) | 2009-07-15 | 2012-03-14 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| DK3199172T3 (en) * | 2009-08-20 | 2018-10-08 | Yeda Res & Dev | DOSAGE regimen for multiple sclerosis |
| ITMI20092069A1 (it) | 2009-11-25 | 2011-05-26 | Biofer Spa | Metodo per ottenere una miscela di fattori biologici isolati da colostro e miscela di fattori biologici attivi derivata da colostro. |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| ES2602977T3 (es) | 2010-10-11 | 2017-02-23 | Teva Pharmaceutical Industries Ltd. | Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero |
| EP2675824B1 (en) | 2011-02-14 | 2017-09-27 | USV Private Limited | Copolymer-1, process for preparation and analytical methods thereof |
| US8575198B1 (en) * | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
| EA201490749A1 (ru) | 2011-10-10 | 2014-09-30 | Тева Фармасьютикал Индастриз Лтд. | Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат |
| US10793307B2 (en) * | 2012-07-06 | 2020-10-06 | 3-D Matrix, Ltd. | Fill-finish process for peptide solutions |
| NZ630421A (en) | 2012-10-10 | 2018-07-27 | Teva Pharma | Biomarkers predictive for clinical response for glatiramer acetate |
| EA201591251A1 (ru) | 2013-01-04 | 2016-05-31 | Тева Фармасьютикал Индастриз Лтд. | Характеризация лекарственного продукта, родственного ацетату глатирамера |
| WO2014128079A1 (en) | 2013-02-19 | 2014-08-28 | Synthon B.V. | Glatiramer acetate multidose formulation |
| CA2903127A1 (en) | 2013-03-12 | 2014-10-09 | Teva Pharmaceutical Industries Ltd. | Rituximab induction therapy followed by glatiramer acetate therapy |
| CN103169670B (zh) * | 2013-03-22 | 2016-07-06 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷微球及其制备方法 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
-
2015
- 2015-01-28 US US14/608,126 patent/US9155775B1/en active Active
- 2015-09-21 KR KR1020177012458A patent/KR102268210B1/ko active IP Right Grant
- 2015-09-21 UA UAA201610444A patent/UA116060C2/uk unknown
- 2015-09-21 MX MX2016011219A patent/MX352734B/es active IP Right Grant
- 2015-09-21 CN CN201580071551.XA patent/CN107530394B/zh active Active
- 2015-09-21 US US14/860,053 patent/US9763993B2/en active Active
- 2015-09-21 PE PE2016001955A patent/PE20170296A1/es unknown
- 2015-09-21 US US15/510,156 patent/US20170312331A1/en not_active Abandoned
- 2015-09-21 RU RU2017104222A patent/RU2669769C2/ru active
- 2015-09-21 BR BR112016023736A patent/BR112016023736A2/pt not_active Application Discontinuation
- 2015-09-21 CA CA2945537A patent/CA2945537C/en active Active
- 2015-09-21 KR KR1020167028604A patent/KR101737295B1/ko active IP Right Grant
- 2015-09-21 JP JP2017534813A patent/JP2018503627A/ja not_active Withdrawn
- 2015-09-21 CA CA2965890A patent/CA2965890A1/en not_active Abandoned
- 2015-09-21 EA EA201691790A patent/EA028484B1/ru unknown
- 2015-09-21 AU AU2015380381A patent/AU2015380381B2/en active Active
- 2015-09-21 EP EP15880609.1A patent/EP3113785A4/en not_active Withdrawn
- 2015-09-21 WO PCT/US2015/051203 patent/WO2016122722A1/en active Application Filing
- 2015-09-24 SI SI201530058A patent/SI3050556T1/sl unknown
- 2015-09-24 DK DK15186721.5T patent/DK3050556T3/en active
- 2015-09-24 EP EP15186721.5A patent/EP3050556B1/en not_active Revoked
- 2015-09-24 PT PT151867215T patent/PT3050556T/pt unknown
- 2015-09-24 EP EP17162112.1A patent/EP3238706A1/en not_active Withdrawn
- 2015-09-24 ES ES15186721.5T patent/ES2584190T3/es active Active
- 2015-09-24 HU HUE15186721A patent/HUE034059T2/en unknown
- 2015-09-24 PL PL15186721T patent/PL3050556T3/pl unknown
- 2015-09-24 ME MEP-2017-103A patent/ME02721B/me unknown
- 2015-09-24 LT LTEP15186721.5T patent/LT3050556T/lt unknown
- 2015-09-24 RS RS20170439A patent/RS55959B1/sr unknown
- 2015-09-25 EA EA201791555A patent/EA201791555A3/ru unknown
- 2015-09-25 EA EA201500881A patent/EA028811B1/ru unknown
- 2015-09-25 AR ARP150103103A patent/AR102096A1/es unknown
-
2016
- 2016-08-16 AU AU2016101453A patent/AU2016101453B4/en not_active Expired
- 2016-09-15 IL IL247851A patent/IL247851A0/en unknown
- 2016-10-07 ZA ZA2016/06903A patent/ZA201606903B/en unknown
- 2016-10-13 CL CL2016002607A patent/CL2016002607A1/es unknown
- 2016-12-01 HK HK16113726A patent/HK1225309B/zh unknown
- 2016-12-14 AU AU2016273881A patent/AU2016273881A1/en not_active Abandoned
-
2017
- 2017-03-28 US US15/471,765 patent/US20170196930A1/en not_active Abandoned
- 2017-04-13 CY CY20171100442T patent/CY1118826T1/el unknown
- 2017-04-21 HR HRP20170625TT patent/HRP20170625T1/hr unknown
- 2017-09-18 US US15/707,378 patent/US20180000884A1/en not_active Abandoned
- 2017-10-19 US US15/788,698 patent/US20180036363A1/en not_active Abandoned
-
2018
- 2018-01-23 AU AU2018200518A patent/AU2018200518A1/en not_active Abandoned
- 2018-07-17 JP JP2018134124A patent/JP6592150B2/ja active Active
-
2019
- 2019-06-06 IL IL267152A patent/IL267152A/en unknown
-
2020
- 2020-09-24 IL IL277601A patent/IL277601B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2584190T1 (es) | Proceso para la fabricación de una preparación farmacéutica que contiene acetato de glatiramero | |
| JP7178731B2 (ja) | ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用 | |
| ES2971959T3 (es) | Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2016526039A5 (es) | ||
| AR080586A1 (es) | Tapa con filtro para jeringa y metodo para utilizarla para la adminstracion de una dosis de un medicamento | |
| RU2016152267A (ru) | Композиция для приготовления противоопухолевого средства и способ приготовления противоопухолевого средства на ее основе | |
| RU2118156C1 (ru) | Композиция - лекарственная форма противоартрозного средства глюкозамина гидрохлорида для инъекций | |
| JP2013049687A5 (es) | ||
| Bansal et al. | Therapeutic Application of Bone Marrow-Derived Stem Cells in a Patient with Methanol-Induced Blindness. | |
| RU2568593C1 (ru) | Способ профилактики тромбоцитопении у больных хроническим гепатитом с, получающих комбинированную противовирусную терапию | |
| ES2632810T3 (es) | Suplemento alimenticio natural que compensa los efectos adversos de la vacunación | |
| RU2568894C1 (ru) | Способ профилактики нейтропении у больных хроническим гепатитом с, получающих комбинированную противовирусную терапию | |
| UA145596U (uk) | Спосіб профілактики вірусних захворювань респіраторної групи | |
| RU2010129491A (ru) | Способ лечения и профилактики кариеса зубов | |
| van Zoelen et al. | Dysarthria, difficulty in walking and dizziness | |
| LU et al. | Application of Small Dose of Dexmedetomidine Under the Guidance of Narcotrend During Combined Spinal-Epidural Anesthesia for Elderly Patients | |
| AR093202A1 (es) | Exoterapia para la cura del sida | |
| EA201600331A1 (ru) | Фармацевтическая композиция в форме раствора для внутривенного и внутримышечного введения и способ ее получения | |
| NZ722455B2 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| MX2012003336A (es) | Vacuna de tratamiento para enfermedades degenerativas. | |
| AR098924A1 (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida |